This is the first evidence that ACPA-negative RA can be subdivided at disease onset in clinically relevant subgroups with differences in the likelihood of achieving and maintaining clinical remission after treatment withdrawal. The gene discussed is PRTN3; the disease is rheumatoid arthritis.